Silence Therapeutics plc (SLN) SEC Filings & Earnings Calls

Transaction subject to shareholder and regulatory approvals; risk of delay or failure.

“Customary closing conditions including Silence shareholder approval and court sanction.”

Insider selling / dilution

“Mr. Griffiths sold an aggregate of 5,484,320 ADSs in open market transactions between August 10, 2026 and August 12, 2026 for aggregate sales proceeds of $87.7M.” · word for word

Insider selling / dilution

“Mr. Griffiths sold an aggregate of 5,484,320 ADSs in open market transactions between August 10, 2026 and August 12, 2026 for aggregate sales proceeds of $87.7M.” · word for word

Dilution risk for existing shareholders

“12,962,963 ADSs issued; option for additional 1,944,444 ADSs”

Biotech sector capital market dependency

“Company raising capital through equity offering, typical for clinical-stage biotech”

Partner termination risk

“On March 4, 2026, AstraZeneca notified Silence that they will not pursue further development of SLN312 beyond Phase 1.” · word for word

No approved products

“We do not have any approved products. Accordingly, we have not generated any revenue from product sales.” · word for word

R&D tax credit dependency

“Based on our current forecast, we do not expect to meet the qualifying R&D expenditure threshold for the year ended December 31, 2026; however, we plan to still expect to claim at the R&D intensive rate as we expect to meet conditions for a grace period under the U.K. R&D tax credit regime.” · word for word

No revenue from product sales; dependent on capital markets for funding.

“Revenue was $0 for Q2 2026; cash $72.1M may not sustain operations through late-stage trials.”

No new financial or operational risks identified; filing is a routine corporate presentation update.

“No material changes disclosed beyond pipeline slide.”

History of losses and negative cash flows

“The Group has incurred recurring losses since inception, including net losses of $15.0 million for the three months ended March 31, 2026.” · word for word

Dependence on collaboration partners

“On March 4, 2026, AstraZeneca notified Silence that they will not pursue further development of SLN312 beyond Phase 1.” · word for word

Need for additional funding

“The Group will need to raise additional funding to fund its operating expenses and capital expenditure requirements in relation to its clinical development activities.” · word for word

Clinical trial risks

“The SANRECO Phase 2 trial is fully enrolled and topline results are anticipated in August 2026.” · word for word

Reliance on U.K. R&D tax credit regime

“Based on our current forecast, we do not expect to meet the qualifying R&D expenditure threshold for the year ended December 31, 2026” · word for word

Clinical-stage biotech with no approved products; cash runway limited; Phase 2 topline risk in August 2026.

“Phase 2 SANRECO trial... on-track for topline results in August 2026; cash $70.1M; net loss $15.0M per quarter.”

Significant decline in collaboration revenue from $43.3M to $0.6M, indicating reliance on partnership milestones.

“Collaboration revenue decreased from $43.3 million to $0.6 million.”

AstraZeneca terminated SLN312 development, a key pipeline asset, though Silence regains rights.

“AstraZeneca notified Silence that they will not pursue further development of SLN312 beyond Phase 1.” · word for word

Net loss more than doubled to $88.6M, raising cash burn concerns despite $85.1M cash position.

“Net loss was $88.6 million compared to $45.3 million.”

CEO departure and interim leadership may create strategic uncertainty.

“Former CEO departed; Chairman appointed Interim Principal Executive Officer; CEO search underway.”

Going concern risk due to increasing net losses and no product revenue

“We have incurred net losses in each year since our inception. Our net losses were $88.6 million for the year ended December 31, 2025 and $45.3 million for the year ended December 31, 2024. As of December 31, 2025, we had an accumulated deficit of $562.6 million.” · word for word

Dependence on future financing; potential dilution

“We will require additional financial resources to continue the ongoing development of our product candidates and pursue our business objectives. If we are unable to obtain these additional resources when needed or on acceptable terms, we may be forced to delay or discontinue our planned operations, including clinical testing of our product candidates.” · word for word

Collaboration revenue concentration and termination risk

“In December 2024, Hansoh notified us that it will not pursue further development under the Hansoh Collaboration. This represented the conclusion of all required development activities and commitments under the terms of the Hansoh Collaboration.” · word for word

Clinical trial failure risk

“The ongoing SANRECO Phase 2 clinical trial is fully enrolled, and we anticipate the announcement of initial topline results from the trial in the third quarter of 2026.” · word for word

Cash burn and future capital needs

“Since our inception, we have incurred significant operating losses and negative cash flows. We anticipate that we will continue to incur losses for the foreseeable future.” · word for word

UK R&D tax credit regime changes

“The decrease in benefit in the current year was mainly related to changes in the U.K R&D tax credit regime which apply in respect of accounting periods commencing on or after April 1, 2024.” · word for word

Clinical-stage company with no approved products; reliance on divesiran Phase 2 data in 2026.

“Topline results from SANRECO Phase 2 anticipated in 3Q 2026; no revenue from products.”

Cash runway into 2028 but still pre-revenue; future capital needs uncertain.

“Cash $102.2M funds operations into 2028; history of net operating losses.”